289 related articles for article (PubMed ID: 20856868)
1. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
2. Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.
Chenna BC; Li L; Mellott DM; Zhai X; Siqueira-Neto JL; Calvet Alvarez C; Bernatchez JA; Desormeaux E; Alvarez Hernandez E; Gomez J; McKerrow JH; Cruz-Reyes J; Meek TD
J Med Chem; 2020 Mar; 63(6):3298-3316. PubMed ID: 32125159
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors.
Chen YT; Lira R; Hansell E; McKerrow JH; Roush WR
Bioorg Med Chem Lett; 2008 Nov; 18(22):5860-3. PubMed ID: 18585034
[TBL] [Abstract][Full Text] [Related]
4. The crystal structure of cruzain: a therapeutic target for Chagas' disease.
McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ
J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373
[TBL] [Abstract][Full Text] [Related]
5. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
6. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
7. Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay.
Wiggers HJ; Rocha JR; Fernandes WB; Sesti-Costa R; Carneiro ZA; Cheleski J; da Silva AB; Juliano L; Cezari MH; Silva JS; McKerrow JH; Montanari CA
PLoS Negl Trop Dis; 2013; 7(8):e2370. PubMed ID: 23991231
[TBL] [Abstract][Full Text] [Related]
8. Cruzain : the path from target validation to the clinic.
Sajid M; Robertson SA; Brinen LS; McKerrow JH
Adv Exp Med Biol; 2011; 712():100-15. PubMed ID: 21660661
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.
Jones BD; Tochowicz A; Tang Y; Cameron MD; McCall LI; Hirata K; Siqueira-Neto JL; Reed SL; McKerrow JH; Roush WR
ACS Med Chem Lett; 2016 Jan; 7(1):77-82. PubMed ID: 26819670
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
12. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of the secretory pathway in cysteine protease inhibitor-resistant Trypanosoma cruzi.
Engel JC; Torres C; Hsieh I; Doyle PS; McKerrow JH
J Cell Sci; 2000 Apr; 113 ( Pt 8)():1345-54. PubMed ID: 10725218
[TBL] [Abstract][Full Text] [Related]
14. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
Roush WR; Cheng J; Knapp-Reed B; Alvarez-Hernandez A; McKerrow JH; Hansell E; Engel JC
Bioorg Med Chem Lett; 2001 Oct; 11(20):2759-62. PubMed ID: 11591518
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of
Prates JLB; Lopes JR; Chin CM; Ferreira EI; Dos Santos JL; Scarim CB
Curr Med Chem; 2024; 31(16):2285-2308. PubMed ID: 37888814
[TBL] [Abstract][Full Text] [Related]
16. Mapping inhibitor binding modes on an active cysteine protease via nuclear magnetic resonance spectroscopy.
Lee GM; Balouch E; Goetz DH; Lazic A; McKerrow JH; Craik CS
Biochemistry; 2012 Dec; 51(50):10087-98. PubMed ID: 23181936
[TBL] [Abstract][Full Text] [Related]
17. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Engel JC; Doyle PS; Palmer J; Hsieh I; Bainton DF; McKerrow JH
J Cell Sci; 1998 Mar; 111 ( Pt 5)():597-606. PubMed ID: 9454733
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors.
Pauli I; Ferreira LG; de Souza ML; Oliva G; Ferreira RS; Dessoy MA; Slafer BW; Dias LC; Andricopulo AD
Future Med Chem; 2017 May; 9(7):641-657. PubMed ID: 28509592
[TBL] [Abstract][Full Text] [Related]
19. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.
Engel JC; Doyle PS; Hsieh I; McKerrow JH
J Exp Med; 1998 Aug; 188(4):725-34. PubMed ID: 9705954
[TBL] [Abstract][Full Text] [Related]
20. The Trypanosoma cruzi protease cruzain mediates immune evasion.
Doyle PS; Zhou YM; Hsieh I; Greenbaum DC; McKerrow JH; Engel JC
PLoS Pathog; 2011 Sep; 7(9):e1002139. PubMed ID: 21909255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
